Kanako Bokuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kanako Bokuda has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Atsuhiro Ichihara
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo, Japan
6 shared publications Noriyoshi Takano
Department of Internal Medicine, Tokyo Women's Medical University , Tokyo, 162-8666 , Japan
5 shared publications- Satoshi Morimoto
Department of Medicine, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan
5 shared publications - Kaoru Yamashita
Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Shinjuku 162-8666, Japan
4 shared publications Yasufumi Seki
Tokyo Women's Medical University , Tokyo , Japan
3 shared publications- Daisuke Watanabe
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2 shared publications
Latest Publications
- Open Access
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- 2 November 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (12) , bvad137
Open AccessEffect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
Context GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear. Objective We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels. Methods We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year after the pituitary surgery in patients with nonfunctioning pituitary neuroendocrine tumor or Rathke cleft cyst. Results Among 171 patients, 55 (32%) presented with severe GHD (peak GH response to GH-releasing peptide-2 < 9 ng/mL). Serum hs-CRP levels were significantly higher in patients with severe GHD than in those without (P < .001) and significantly correlated with the peak GH (r = −0.50, P < .001). Multiple regression analyses showed that the peak GH significantly and negatively predicted hs-CRP levels (β = −0.345; 95% CI, −0.533 to −0.158) and the lowest quartile of the peak GH (<5.04 ng/mL) were significantly associated with increase in hs-CRP levels (exp [β] = 1.840; 95% CI, 1.209 to 2.801), after controlling for other anterior hormones and metabolic parameters. Postoperative change in the peak GH (N = 60) significantly predicted change in hs-CRP levels (β = −0.391; 95% CI, −0.675 to −0.108), independent of alterations in other anterior hormones and metabolic parameters. Conclusion The inverse association between GH secretion and hs-CRP levels highlights the protective role of GH in the increase in hs-CRP.
- Open Access
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- 20 October 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 688-700
Open AccessEffects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed. Here, we investigated the effects of 24-week monotherapy with aliskiren compared to amlodipine in hypertensive patients with type 2 diabetes or obesity. Methods: In this randomized intervention study, 62 adult hypertensive patients with visceral obesity (defined as a body mass index [BMI] greater than 25 kg/m2 and a visceral adipose tissue area [VFA] greater than 100 cm2) or type 2 diabetes mellitus (age 57 ± 13, 65% men, BMI 28.8 ± 4.8 kg/m2, VFA 134.8 ± 47.0 cm2, blood pressure 141 ± 16/86 ± 13 mm Hg) were randomized to receive 24-week treatment with aliskiren (max. 300 mg) or amlodipine (max. 10 mg). The primary outcome was the change in VFA at 24 weeks post-treatment. Results: Change in VFA did not differ significantly from baseline in either group. Systolic blood pressure significantly decreased at 12 weeks (−10 mm Hg, p = 0.001) and 24 weeks (−10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (−11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (−6 mm Hg, p = 0.009) only in the amlodipine group. Although the estimated glomerular filtration rates did not significantly change in either group, the logarithm of urinary albumin excretion significantly decreased at 24 weeks only in the aliskiren group (−0.60, p < 0.001). The 24-week changes in the urinary albumin excretion significantly correlated with the changes in the plasma renin activity in the aliskiren group (r = 0.51, p = 0.008). Conclusion: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
- Open Access
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
THU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors
Disclosure: Y. Seki: None. S. Morimoto: None. K. Bokuda: None. D. Watanabe: None. S. Watanabe: None. K. Yamashita: None. N. Takano: None. A. Ichihara: None. Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. Serum high-sensitivity C-reactive protein (hs-CRP) levels has been reported to estimate those risks. GH supplementation therapy was reported to decrease the serum hs-CRP levels in GH deficient patients, however, the association between GH secretion and serum hs-CRP levels have been unclear. Patients and Methods: We retrospectively reviewed charts of the patients with non-functioning pituitary adenoma and Rathke’s cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests to assess GH secretion, and investigated the association between GH secretion and background characteristics. Patients who had a history of pituitary surgery, severe renal insufficiency or active inflammatory diseases, or received GH supplementation therapy were excluded. Results: Among 171 patients (100 NFPA and 71 Rathke’s cysts), 55 (32%) presented severe GH deficiency, as diagnosed using GHRP-2 tests. Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (754 [393—1330] vs 249 [113—537] ng/mL, P < 0.001). Serum hs-CRP levels were significantly correlated with logarithm of peak GH response to GHRP-2 (r = -0.50, P < 0.001), but not with IGF-1 SD score (r = -0.10, P = 0.21). In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.001) after adjustment with age, sex, BMI, smoking habit, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, abnormal liver function, and other pituitary hormone deficiencies. Severe GH deficiency were significantly associated with for serum hs-CRP levels higher than 1000 ng/mL (Odds ratio, 2.58 ;95% Confidence interval 1.15-5.78) when adjusted for obesity and abnormal liver function. Conclusion: GH secretion was significantly and negatively associated with serum hs-CRP levels independent of atherosclerotic risk factors, metabolic complications of GH deficiency, and other anterior pituitary hormone secretions. Presentation: Thursday, June 15, 2023
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
Open AccessTHU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors
Disclosure: Y. Seki: None. S. Morimoto: None. K. Bokuda: None. D. Watanabe: None. S. Watanabe: None. K. Yamashita: None. N. Takano: None. A. Ichihara: None. Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. Serum high-sensitivity C-reactive protein (hs-CRP) levels has been reported to estimate those risks. GH supplementation therapy was reported to decrease the serum hs-CRP levels in GH deficient patients, however, the association between GH secretion and serum hs-CRP levels have been unclear. Patients and Methods: We retrospectively reviewed charts of the patients with non-functioning pituitary adenoma and Rathke’s cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests to assess GH secretion, and investigated the association between GH secretion and background characteristics. Patients who had a history of pituitary surgery, severe renal insufficiency or active inflammatory diseases, or received GH supplementation therapy were excluded. Results: Among 171 patients (100 NFPA and 71 Rathke’s cysts), 55 (32%) presented severe GH deficiency, as diagnosed using GHRP-2 tests. Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (754 [393—1330] vs 249 [113—537] ng/mL, P < 0.001). Serum hs-CRP levels were significantly correlated with logarithm of peak GH response to GHRP-2 (r = -0.50, P < 0.001), but not with IGF-1 SD score (r = -0.10, P = 0.21). In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.001) after adjustment with age, sex, BMI, smoking habit, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, abnormal liver function, and other pituitary hormone deficiencies. Severe GH deficiency were significantly associated with for serum hs-CRP levels higher than 1000 ng/mL (Odds ratio, 2.58 ;95% Confidence interval 1.15-5.78) when adjusted for obesity and abnormal liver function. Conclusion: GH secretion was significantly and negatively associated with serum hs-CRP levels independent of atherosclerotic risk factors, metabolic complications of GH deficiency, and other anterior pituitary hormone secretions. Presentation: Thursday, June 15, 2023
- 2 May 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 90
A negative association between growth hormone secretion and inflammation in adult patients with non-functioning pituitary mass
Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. High-sensitivity C-reactive protein (hs-CRP), an inflammatory marker associated with increased cardiovascular risk, reportedly decreased after GH supplementation in GH-deficient patients, however, the association between GH secretion and inflammation remains unclear. Patients and Methods: We retrospectively investigated the association between GH secretion assessed using a GH-releasing peptide-2 (GHRP-2) test and serum hs-CRP level in the patients with non-functioning pituitary neuroendocrine tumor (NF-PitNET) and Rathke’s cleft cyst (RCC). Patients with severe renal insufficiency, active inflammatory and malignant diseases, and a history of pituitary surgery, and under GH supplementation therapy were excluded. Results: Among 171 patients (100 NF-PitNET and 71 RCC), 55 (32%) presented severe GHD. Serum hs-CRP levels were significantly higher in the patients with severe GHD than those without (754 [393-1330] vs 249 [113-537] ng/ml, P r=-0.50, P 1000 ng/ml) (adjusted odds ratio, 2.55; 95% confidence interval 1.15-5.70). In the 60 patients who received pituitary surgeries, the postoperative changes in peak GH response to GHRP-2 (β = -0.320, P = 0.025) significantly estimated those in serum hs-CRP levels independent of other anterior hormone secretions. Conclusions: The negative association between GH secretion and serum hs-CRP levels suggested an important role of impaired GH secretion in the increased cardiovascular risks through the development of inflammation.
- 2 May 2023
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 90
A negative association between growth hormone secretion and inflammation in adult patients with non-functioning pituitary mass
Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. High-sensitivity C-reactive protein (hs-CRP), an inflammatory marker associated with increased cardiovascular risk, reportedly decreased after GH supplementation in GH-deficient patients, however, the association between GH secretion and inflammation remains unclear. Patients and Methods: We retrospectively investigated the association between GH secretion assessed using a GH-releasing peptide-2 (GHRP-2) test and serum hs-CRP level in the patients with non-functioning pituitary neuroendocrine tumor (NF-PitNET) and Rathke’s cleft cyst (RCC). Patients with severe renal insufficiency, active inflammatory and malignant diseases, and a history of pituitary surgery, and under GH supplementation therapy were excluded. Results: Among 171 patients (100 NF-PitNET and 71 RCC), 55 (32%) presented severe GHD. Serum hs-CRP levels were significantly higher in the patients with severe GHD than those without (754 [393-1330] vs 249 [113-537] ng/ml, P r=-0.50, P 1000 ng/ml) (adjusted odds ratio, 2.55; 95% confidence interval 1.15-5.70). In the 60 patients who received pituitary surgeries, the postoperative changes in peak GH response to GHRP-2 (β = -0.320, P = 0.025) significantly estimated those in serum hs-CRP levels independent of other anterior hormone secretions. Conclusions: The negative association between GH secretion and serum hs-CRP levels suggested an important role of impaired GH secretion in the increased cardiovascular risks through the development of inflammation.
- Open Access
- 27 September 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-9
Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
Objective. Persistence of hyperparathyroidism (HPT) after renal transplantation leads to undesirable outcomes such as increase in cardiovascular events, graft dysfunction, and increased mortality. Options for therapy include medical management with calcimimetic or operative management. The present study was undertaken to evaluate the natural history of HPT after renal transplantation and to determine risk factors for persistent HPT in the era of calcimimetic. Design. The study is a retrospective review of data from 74 consecutive patients who underwent renal transplantation at our institution from April 2011 to November 2019. Methods. The natural history of HPT after renal transplantation and associations between intact parathyroid hormone (PTH) level after transplantation and clinical variables such as age, sex, duration of pretransplant dialysis, and use of calcimimetic before transplantation were evaluated. Results. Intact PTH decreased after renal transplantation in most of the patients without receiving parathyroidectomy. Known risk factors of persistent HPT did not associate with intact PTH level after renal transplantation in patients who had been receiving calcimimetic before transplantation. Conclusion. In conclusion, we have found that HPT after renal transplantation could be managed successfully by medical treatments. When predicting the prognosis of HPT after transplantation, pretransplant use of calcimimetic should be taken into consideration.
- 27 September 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-9
Open AccessEffect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
Objective. Persistence of hyperparathyroidism (HPT) after renal transplantation leads to undesirable outcomes such as increase in cardiovascular events, graft dysfunction, and increased mortality. Options for therapy include medical management with calcimimetic or operative management. The present study was undertaken to evaluate the natural history of HPT after renal transplantation and to determine risk factors for persistent HPT in the era of calcimimetic. Design. The study is a retrospective review of data from 74 consecutive patients who underwent renal transplantation at our institution from April 2011 to November 2019. Methods. The natural history of HPT after renal transplantation and associations between intact parathyroid hormone (PTH) level after transplantation and clinical variables such as age, sex, duration of pretransplant dialysis, and use of calcimimetic before transplantation were evaluated. Results. Intact PTH decreased after renal transplantation in most of the patients without receiving parathyroidectomy. Known risk factors of persistent HPT did not associate with intact PTH level after renal transplantation in patients who had been receiving calcimimetic before transplantation. Conclusion. In conclusion, we have found that HPT after renal transplantation could be managed successfully by medical treatments. When predicting the prognosis of HPT after transplantation, pretransplant use of calcimimetic should be taken into consideration.
- Open Access
- 1 September 2012
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 30 (Supplement) , e296
1022 STRUCTURAL AND FUNCTIONAL ANALYSIS OF (PRO)RENIN RECEPTOR IN ASSOCIATION WITH V-ATPASE
Background: As a key player in the local renin-angiotensin system (RAS), (pro)renin receptor (PRR) activation is involved in the development of cardiac fibrosis and proteinuria in hypertension and diabetes. The PRR contains four different domains: an N-terminal signal peptide, an extracellular domain (ECD), a single transmembrane domain (TM) and a short cytosolic domain (CD). PRR undergoes cleavage by furin in the trans-Golgi network to generate a N-terminal soluble fragment (NTF), which is secreted outside the cell, along with a C-terminal residue (CTF) that is associated with the vacuolar H+-ATPase (V-ATPase). While PRR is essential for assembly of V-ATPase, exact domains that need for V-ATPase assembly remain determined. Methods: We performed rescue experiments, where several different constructs of PRR were overexpressed in PRR-null mouse embryonic fibroblasts (MEF). Protein expressions of V-ATPase subunits were analyzed in Western Blot analysis. Acidification of intracellular compartments was evaluated by LysoTracker staining. Results: While PRR-null MEF demonstrated reduced expression of membrane-bound Vo subunits of V-ATPase and decreased staining of LysoTracker, full-length PRR overexpression in PRR-null MEF completely rescued expressions of V-ATPase subunits and LysoTracker staining. ECD+TM overexpression similarly abrogated the reduction of V-ATPase subunits expression and LysoTracker staining, while CTF overexpression failed to cancel these effects. Interestingly, mutant PRR that cannot be cleaved by furin also successfully recovered expressions of V-ATPase subunits and LysoTracker staining. Conclusions: ECD and TM of PRR are essential for assembly of V-ATPase.
- 1 September 2012
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 30 (Supplement) , e296
Open Access1022 STRUCTURAL AND FUNCTIONAL ANALYSIS OF (PRO)RENIN RECEPTOR IN ASSOCIATION WITH V-ATPASE
Background: As a key player in the local renin-angiotensin system (RAS), (pro)renin receptor (PRR) activation is involved in the development of cardiac fibrosis and proteinuria in hypertension and diabetes. The PRR contains four different domains: an N-terminal signal peptide, an extracellular domain (ECD), a single transmembrane domain (TM) and a short cytosolic domain (CD). PRR undergoes cleavage by furin in the trans-Golgi network to generate a N-terminal soluble fragment (NTF), which is secreted outside the cell, along with a C-terminal residue (CTF) that is associated with the vacuolar H+-ATPase (V-ATPase). While PRR is essential for assembly of V-ATPase, exact domains that need for V-ATPase assembly remain determined. Methods: We performed rescue experiments, where several different constructs of PRR were overexpressed in PRR-null mouse embryonic fibroblasts (MEF). Protein expressions of V-ATPase subunits were analyzed in Western Blot analysis. Acidification of intracellular compartments was evaluated by LysoTracker staining. Results: While PRR-null MEF demonstrated reduced expression of membrane-bound Vo subunits of V-ATPase and decreased staining of LysoTracker, full-length PRR overexpression in PRR-null MEF completely rescued expressions of V-ATPase subunits and LysoTracker staining. ECD+TM overexpression similarly abrogated the reduction of V-ATPase subunits expression and LysoTracker staining, while CTF overexpression failed to cancel these effects. Interestingly, mutant PRR that cannot be cleaved by furin also successfully recovered expressions of V-ATPase subunits and LysoTracker staining. Conclusions: ECD and TM of PRR are essential for assembly of V-ATPase.
- Open Access
- 1 January 2011
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 44 (10) , 1047-1052
Multiple abscess formation in an HD patient
慢性腎不全維持血液透析中,低栄養,鉄過剰症,骨髄異形成症候群(MDS)など複数の免疫能低下に寄与する要因が重なり,メチシリン感受性黄色ブドウ球菌(MSSA)によるシャント感染・敗血症を契機に多発膿瘍の合併に至った症例を経験した.透析患者のシャント感染を契機に,本症例のような重症多発性化膿性膿瘍を合併することはまれであり,文献的考察を加え報告する.症例は67歳,女性.慢性糸球体腎炎を原病として,慢性腎不全の進行に伴い,1988年に血液透析導入となった.1993年骨髄穿刺の結果骨髄異形成症候群と診断され(染色体異常なし),2007年から適宜赤血球輸血を施行されていた(合計40単位).2010年1月14日血液透析施行中40度の発熱があり,両下肢痛と腰部痛が出現した.インフルエンザ迅速試験陰性で解熱鎮痛薬を処方されるも改善せず,1月19日WBC 8,600/μL,CRP 46.75mg/dLであり,精査加療目的で同日当院へ緊急入院した.Vancomycin hydrochloride(VCM),meropenem hydrate(MEPM)を開始したが,第3病日,血液培養でMSSAが検出されたため,第4病日からcefazolin sodium(CEZ)へ変更した.Gaシンチグラフィ,MRI,CTなど各種画像検査および眼科検査で,シャント部皮下膿瘍,腰部硬膜外膿瘍,腰部脊椎炎・椎間板炎,多発化膿性関節炎,腰部化膿性筋炎・傍脊柱筋筋肉内膿瘍,多発性細菌性肺塞栓,右眼内炎が認められ,シャント皮下膿瘍から播種性に全身膿瘍をきたしたと考えられた.CEZを継続したところ,血液培養は陰性化し,各感染巣は縮小,消失した.本症例は維持透析,MDS,低栄養,鉄過剰症などのさまざまな易感染性の要素を有していたため,非常にまれな重症多発性感染巣が形成されたと考えられた.このような複数の易感染傾向を有する患者では特に日常の感染対策が必須である.今後,易感染性の末期腎不全患者の増加が見込まれるが,感染症の予防という点から,感染のリスク要因を極力排除し,症状出現時における早急な検査,診断を進めることが重要である.
- 1 January 2011
- Published by Japanese Society for Dialysis Therapy in Nihon Toseki Igakkai Zasshi
- Vol. 44 (10) , 1047-1052
Open AccessMultiple abscess formation in an HD patient
慢性腎不全維持血液透析中,低栄養,鉄過剰症,骨髄異形成症候群(MDS)など複数の免疫能低下に寄与する要因が重なり,メチシリン感受性黄色ブドウ球菌(MSSA)によるシャント感染・敗血症を契機に多発膿瘍の合併に至った症例を経験した.透析患者のシャント感染を契機に,本症例のような重症多発性化膿性膿瘍を合併することはまれであり,文献的考察を加え報告する.症例は67歳,女性.慢性糸球体腎炎を原病として,慢性腎不全の進行に伴い,1988年に血液透析導入となった.1993年骨髄穿刺の結果骨髄異形成症候群と診断され(染色体異常なし),2007年から適宜赤血球輸血を施行されていた(合計40単位).2010年1月14日血液透析施行中40度の発熱があり,両下肢痛と腰部痛が出現した.インフルエンザ迅速試験陰性で解熱鎮痛薬を処方されるも改善せず,1月19日WBC 8,600/μL,CRP 46.75mg/dLであり,精査加療目的で同日当院へ緊急入院した.Vancomycin hydrochloride(VCM),meropenem hydrate(MEPM)を開始したが,第3病日,血液培養でMSSAが検出されたため,第4病日からcefazolin sodium(CEZ)へ変更した.Gaシンチグラフィ,MRI,CTなど各種画像検査および眼科検査で,シャント部皮下膿瘍,腰部硬膜外膿瘍,腰部脊椎炎・椎間板炎,多発化膿性関節炎,腰部化膿性筋炎・傍脊柱筋筋肉内膿瘍,多発性細菌性肺塞栓,右眼内炎が認められ,シャント皮下膿瘍から播種性に全身膿瘍をきたしたと考えられた.CEZを継続したところ,血液培養は陰性化し,各感染巣は縮小,消失した.本症例は維持透析,MDS,低栄養,鉄過剰症などのさまざまな易感染性の要素を有していたため,非常にまれな重症多発性感染巣が形成されたと考えられた.このような複数の易感染傾向を有する患者では特に日常の感染対策が必須である.今後,易感染性の末期腎不全患者の増加が見込まれるが,感染症の予防という点から,感染のリスク要因を極力排除し,症状出現時における早急な検査,診断を進めることが重要である.